Search results (9)
« Back to PublicationsBlood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
Journal article
Silk SE. et al, (2024), Lancet Infect Dis, 24, 1105 - 1117
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
Journal article
King LDW. et al, (2024), Cell Rep Med, 5
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.
Journal article
Silk SE. et al, (2023), Med, 4, 668 - 686.e7
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
Journal article
Hou MM. et al, (2023), Sci Transl Med, 15
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.
Journal article
Ragotte RJ. et al, (2021), mSphere, 6
Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.
Journal article
Willcox AC. et al, (2021), Cell Rep Med, 2
IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal Salmonella Develop at Discordant Rates.
Journal article
Schager AE. et al, (2018), mBio, 9